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. '';t: I. Introduction 
;,J..", 
'~ Alpha I-antitrypsin (a I AT) is a 52 kDa alpha I-glycoprotein that is produced by 
hepatocytes and secreted into the blood. where it acts as a circulating serine 
,1'''J'U;4l~C inhibitor (1-4). It is a prototypical .. suicide" protease inhibitor that 
...,IIIJUIIIC" with its complementary serine protease-be it polymorphonuclear 
. serine protease or pancreatic elastase-resulting in its own elimination 
from the plasma. 
alAT deficiency is a heritable autosomal recessive metabolic disease that 
laullS in the synthesis and secretion of a defective alpha I-glycoprotein without 
IDZymatic activity Z form that occurs as a consequence of a single amino acid 
,lUlllStituti'( >n (Gly 342 to Lys 342) (I). It occurs as a result of a single nucleotide 
in the DNA encoding for the normal M form of the serine protease 
_.un'," a 1 AT. 
As noted in earlier chapters. many different alleles for the alAT gene exist. 
frequency of various a l AT protease inhibitor (PI) phenotypes in almost a 
IIIXlsaJlld whites in Minnesota is shown in Table I. The most common phenotype 
MI, having a frequency of 0.724 (\). The mutant phenotype responsible for 
deficiency. PiZ. has an estimated frequency of 0.014 (1-5). Thus. the 
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Table 1 Distribution of PI Phenotypes and Allele 
Frequencies in Whites Living in Minnesota 
Phenotypes No. observed Allele frequencies 
MI 478 PI*MI = 0.724 
MIM2 177 PI*M2 = 0.137 
MIM3 121 PI*M3 = 0.095 
MIS 28 PI*S = 0.023 
MIZ 18 PI*Z = 0.014 
MIF 4 PI*F = 0.003 
Mll 5 PI*I = 0.003 
MIP 2 PI*P = O.OO} 
M2 19 Total = 1.000 
M2M3 24 
M2S 4 
M2Z 4 
M3 9 
M3Z 3 
M3S 5 
S 2 
SF 
Total = 904 
frequency of homozygous o.,AT PiZZ individuals can be calculated to be about 
115000 individuals. The nonnal range for o..AT levels in serum is 0.85 to 2.13 
mglml. Individuals who are PiZZ have very low, but not zero, levels of the protein 
in their serum, with levels typically being below 0.3 mglml. 
Individuals who are heterozygotes for the Z allele have reduced levels that 
range from levels half of those of the lower limit of nonnal to nearly nonnallevels 
(Fig. 1) (1,6-16). [n contrast, heterozygotes with alleles other than Z often have 
increased levels of o..AT in their serum, as shown in Figure I (6-16). 
II. a1AT Deficiency and Liver Disease 
Individuals with o.,AT deficiency are uniquely susceptible to the development of 
two disease processes (1-3): panacinar early-onset emphysema and hepatocellu-
lar liver disease that presents as either neonatal hepatitis (17-23) in infants or 
severe protein synthetic liver failure in adults (24-37). The latter presumably 
occurs as a result of an intrahepatic accumulation of abnonnal 0., AT protein with-
in hepatocytes (38,39). 
In a review of the cause of death of adults with 0., AT. 69% were reponed to 
alAT De. 
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Figure 1 Serum a I AT levels in heterozygotes with and without a Z allele. 
have died as a direct result of either respiratory failure associated with emphysema 
or a complication of their pulmonary disease (25). A much smaller fraction. 13%. 
died as result of either hepatic failure or bleeding esophageal varices (Fig. 2) 
(27.29-32.34,35). As impressive as these figures are, they underestimate the 
problem of liver disease as a cause of death in individuals with at AT deficiency, as 
the study from which these data were obtained examined the case of death of only 
adults with PiZZ atAT deficiency and. as a result, failed to include deaths as a 
result of a t AT deficiency occurring in children (17-23). In the latter cases. 
essentially all the deaths are a result of liver disease or one of its complications. 
• such as ponal hypenension. In our own experience, the number of cases with 
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Figure 2 Cause of death in adults with a 1 AT deficiency. 
alAT liver disease presenting for liver transplantation in infants or children 
exceeds the number of cases of adults who present with liver disease due to alAT 
deficiency. If the deaths that occur in both children and adults with alAT defi-
ciency were determined, it would appear that liver disease accounts for 59% of the 
total deaths whereas pulmonary disease accounts for 23%. Even these figures 
underestimate the role of alAT as a cause of lethal liver disease because an 
increased prevalence of "cryptogenic" cirrhosis associated with alAT hetero-
zygotes for the PiZ allele (particularly MZ) has been reported and the deaths of 
these individuals would not be included in these totals (7-15,40-42). 
Neonatal hepatitis is a common clinical presentation of individuals with 
alAT deficiency during infancy (17-23,37). Almost 30% of infants with neonatal 
hepatitis ultimately can be shown to be homozygous for the Z allele. Nearly 6% of 
the cases of neonatal hepatitis will be heterozygotes (MZ) for the Z allele. Thus, 
the prevalence of neonatal hepatitis in a l AT Z heterozygotes is twice that seen in 
individuals who have a "normal" MM phenotype. As noted above, adults with 
cryptogenic cirrhosis have a statistically increased incidence of heterozygosity for 
the Z allele (p < 0.001), which is almost ten-fold greater than the rate of 
cryptogenic cirrhosis in large, clinical liver-disease populations (Fig. 3) (7-
16.40-42). Interestingly, the rates of autoimmune, viral. and alcoholic liver 
disease in alAT heterozygotes for the Z allele appear to be reduced by about 50%. 
Only the reduction in the prevalence of alcoholic liver disease, however, achieved 
a level of statistical significance (p < 0.01). 
More recently, the relationship between a,AT deficiency and liver disease 
has been shown to be more complex than simply a deficiency of a normal 
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Figure 3 Frequency of Z allele in patients with cryptogenic cirrhosis seen as adults. 
circulating secretory serine protease; it may also involve immunological or at least 
genetic factors. as the rate of a, AT deficiency with liver disease is almost threefold 
higher (X2 = 7.124; p < 0.01) in individuals who are HLA Or3-positive (43.44). 
In contrast. HLA Or4 appears to be protective. with a halving of the rate of liver 
disease in individuals who are homozygous for the Z allele (X 2 = 4.010; p < 0.05). 
The observation that HLA Dr3 occurs at an increased frequency in patients with 
o.,AT deficiency and liver disease. however. could not be confinned in our own 
series of orthotopic liver-transplant (OLTx) patients (45). Nonetheless. RFIP 
studies have noted that the association with HLA Dr3 and 0. ,AT-deficiency liver 
disease is associated with the Ow24 and Ow25 SUbtypes (both p < 0.05) and that 
both Or3 Ow24 and Or3 Ow25 occur two and four times more frequently in 
individuals with 0.1AT deficiency and liver disease than in controls (42.43). 
The role of other genetic or environmental factors in the pathogenesis of the 
liver disease associated with 0. 1 AT deficiency and the Z allele is either less clear or 
totally unknown (46). It should be noted. however. that a role for environmental 
factors may exist. as is the situation with smoking and the association of 0.1AT 
deficiency and panacinar emphysema (1.2.24.46.47). Individuals who smoke and 
are homozygous for the Z allele develop clinically evident emphysema a full 
decade or more earlier than do homozygotes who do not smoke (1-3). 
376 Van Thiel and Stant 
The clinical presentation of children with CI,AT deficiency is rather consis-
tent, with greater than 75% presenting with neonatal hepatitis (jaundice) and 
smaller numbers presenting with either asymptomatic hepatosplenomegaly or 
hematemesis (Fig. 4) (17-23). In the vast majority of cases with neonatal hepa-
titis, the jaundice resolves within 8 months. A minority «20%) die in the first 
year of life, usually in the seventh or eighth month of life. Most, however, do not 
die but live to develop liver disease that requires transplantation as either an older 
child or an adult. Table 2 shows the differential diagnosis of CI, AT disease in 
children segmented into those who present initially with evidence for liver disease 
as infants « I year of age) and those who are more than I year old at the time of 
initial presentation. In most cases, after the initial period of neonatal hepatitis 
characterized by cholestasis, the disease progresses as does any other hepatocellu-
lar disease, with the development of portal hypertension and protein synthetic 
defects that characterize the disease process. Six clinical findings are used to 
identify children with CI, AT deficiency who have a poor prognosis: the presence of 
hepatomegaly, a palpably hard liver, failure to thrive, clubbing of fingers, and two 
or more overt signs of portal hypertension (ascites and varices). Typically, the 
disease in children follows a characteristic histopathological progression from 
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Figure 4 Frequency of various types of c1incal presentations of children with a lAT 
deficiency. 
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Table 2 Differential Diagnosis of a I AT-Deficiency Liver Disease 
Neonates to 1 year 
Neonatal hepatitis 
TORCH" 
Blood-group incompatibility 
Cystic fibrosis 
Galactosemia 
Tyrosinemia 
>1 year 
Cystic fibrosis 
Autoimmune chronic active hepatitis 
Wilson's disease 
Microcytic Ii ver disease 
Congenital hepatic fibrosis 
Chronic viral hepatitis 
q'ORCH = tox.oplasmosis. rubella, cytomegalovirus hepatitis. 
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the newborn period through 2 years of age, when cirrhosis is usually present 
(Table 3). Signs and symptoms of portal hypertension typically occur after age 
2 and lead to a need for transplantation or to death by age 8 ± 0.3 years (range 8 
months to 13 years) (Fig. 4). 
The situation is quite similar in adults. with most cases either giving a 
history of neonatal jaundice or silently developing cirrhosis that presents clini-
cally when a complication of the cirrhosis becomes evident. typically, a problem 
related to portal hypertension such as ascites. variceal bleeding. or hepatic 
encephalopathy (24-37). 
III. Liver Transplantation 
Table 4 shows the frequency of the dominant clinical features of patients with 
a,AT deficiency at a time point immediately prior to OLTx. Table 5 shows the age 
distribution of cases with Q,AT deficiency who have received a liver transplant in 
Pittsburgh. Table 6 shows the percentage of the total cases on an annual basis who 
were transplanted in Pittsburgh for Q,AT deficiency. As is evident from Table 5. 
two peaks in age at time of OLTx occur: the first at ages 2-11 years and the second 
between 18 and 59 years. Table 6 shows that the fraction of total transplant cases 
Table 3 Hepatic Histology in Children 
with a I AT Deficiency Liver Disease: Effect 
of Age 
Giant cell hepatitis 
Hepatitis 
Portal fibrosis 
Cirrhosis 
3 months or less 
3 months to 3 years 
4 months to 18 years 
6 months to 18 months 
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Features in Patients with 
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alAT Deficiency 1 
Immediately Before Liver 
Transplantation 
Clinical features % 
Ascites 80 
Variceal hemorrhage 59 
Jaundice 38 
Encephalopathy 10 
with alAT deficiency has remained rather stable through the years, ranging from 
4 to 90/0, with minor variations above this figure. 
The rate of graft and patient survival following liver transplantation for all 
cases with a 1 AT deficiency is 680/0 and 760/0, respectively, through S years (Figure 
SA). The rate of graft and patient survival for children and adults with alAT 
deficiency through 5 years is shown in Figure 58. Little difference in graft 
survival is evident. but patient survival through S years is clearly better for 
children (810/0) than it is for adults 010/0). The vast majority of cases (81.3%) 
require only one graft: 13.S0/0 require a second graft and 5.20/0 require a third graft. 
As for the technical details of the transplant operation. because most cases 
with alAT deficiency are neither very young « 1 year of age) nor very old (>()) 
years of age), little or no surgical difficulty is experienced as a result of the 
required vascular of biliary-tract reconstructions. The major problem during the 
operative procedure is a result of the portal hypertension and coagulopathy that 
characterize the disease. In adults. this problem is resolved in large measure as a 
result of the use of the portal systemic bypass developed by Denmark et al. (49) 
and used initially by Shaw et al. (50). In children. the bypass is frequently not used 
Table 5 Age Distribution of 
cd AT-Deficient Patients al Time 
of Liver Transplantation 
n IJ, 
Infant (under 2 years) 5 5.2 
Child (2-1 \) 40 41.7 . 
Adolescent ( 12-17) 4 4.2 
Adult ( 18-59) 39 40.6 
Senior (over 60) 8 8.3 
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Table 6 Number of 
Cases Transplanted for 
alAT Deficiency and the 
Years in Which the 
Transplant Procedure was 
Performed 
n % 
1981 6 6.3 
1982 4 4.2 
1983 7 7.3 
1984 9 9.4 
1985 9 9.4 
1986 15 15.6 
1987 8 8.3 
1988 12 12.5 
1989 8 8.3 
1990 13 13.5 
1991 5 5.2 
Total 96 100.0% 
and bleeding can at times be a difficult management problem during the initial 
parts of the transplant operation. 
Following transplantation. the a,AT phenotype of the serine protease pres-
ent in blood becomes that of the organ donor and the serum level returns to the 
normal range (51-53). As a result. not only is liver function returned to normal 
with OLTx but also the hepatic disease is cured (51-53). Moreover. because of the 
normal serum levels. most likely either the pulmonary disease is stabilized or its 
rate of progression is markedly slowed. This does not occur with portal caval 
shunting. the only other surgical procedure shown to have benefit in children with 
this disease (54.55). A major question that remains to be resolved is whether the 
act of liver replacement also cures or at least halts the progression of the pulmon-
ary disease that occurs as a consequence of a,AT deficiency. Studies to examine 
the serine anti protease activity. cx,AT levels. and phenotype in alveolar lavage 
specimens in long-tenn survivors of OLTx for Ct,AT deficiency are currently in 
progress in Pittsburgh. Similarly. studies characterizing the presence or absence-
and. if present. the severity-of the pulmonary disease in liver recipients follow-
ing successful OLTx for Ct,AT are currently in progress. 
With the recent demonstration that donor lymphodendritic cell seeding from 
liver allografts occurs following successful OLTx (56.57). it has become under-
standable why liver allograft recipients transplanted for metabolic diseases (both 
380 Van Thiel and Starzl 
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hepatically based and nonhepatically based) such as type 4 glycogen storage 
disease (57), type II hyperlipoproteinemia (58), Wilson's disease (59), Wolman's 
disease (60), Nieman-Pick disease (61), Gaucher's disease (unpublished observa-
tions), and seablue histiocyte syndrome (unpublished observations) have experi-
enced benefits well beyond what was anticipated from liver transplantation. 
Because the lungs are natural repositories of dendritic cells. it is to be expected 
that donor-specific a lAT-positive dendritic cells would be found in the bronchi 
and alveolar walls of liver allograft recipients who were a I AT-deficient prior to 
OLTx. The presence of these cells locally in the lungs following OLTx as well as 
the fact that nonnallevels of alAT are achieved in the serum of patients trans-
planted for alAT deficiency would be expected to either slow or. more likely, halt 
the progression of any alAT deficiency-dependent pulmonary disease following 
successful OLTx. 
IV. Conclusion 
Based on these recent observations (56,57), the role that whole-organ transplanta-
tion plays in the management of metabolic disease in general may need to be re-
evaluated. It may well be that all such procedures. regardless of the organ being 
transplanted. result in a gain of metabolic function detennined by the content of 
Iymphodendritic cells that migrate from the donor organ throughout the body of 
the recipient (56.57). The concept that a kidney. spleen. liver. or other organ could 
bring a systemic supply of a missing lyzozomal enzyme has been suggested before 
(62-64) but was abandoned because of the lack of a rationale and the inability to 
demonstrate benefit. 
Even if the abnonnality of a 1 AT deficiency in the lungs were not cured as a 
result of liver transplantation. patient survival and quality of life would be greatly 
enhanced. It appears more likely. however. that because the level of a,AT is either 
nonnal or greatly enhanced as a result of OLTx. the lung disease is likely to be 
stabilized or at least its rate of progression markedly reduced following successful 
OLTx. One might anticipate further that. since the liver disease is cured. the risk 
for the development of a hepatocellular carcinoma would decline dramatically 
(8.65-71). Because individuals with a,AT deficiency are not at increased risk for 
a biliary cancer prior to liver transplantation. following transplantation the risk for 
this condition should not be altered (28). 
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